DZ2564A1 - Compositions pharmaceutiques pour le traitement dudiabète sucre et d'états associés. - Google Patents

Compositions pharmaceutiques pour le traitement dudiabète sucre et d'états associés.

Info

Publication number
DZ2564A1
DZ2564A1 DZ980174A DZ980174A DZ2564A1 DZ 2564 A1 DZ2564 A1 DZ 2564A1 DZ 980174 A DZ980174 A DZ 980174A DZ 980174 A DZ980174 A DZ 980174A DZ 2564 A1 DZ2564 A1 DZ 2564A1
Authority
DZ
Algeria
Prior art keywords
treatment
pharmaceutical compositions
diabetes mellitus
associated conditions
conditions
Prior art date
Application number
DZ980174A
Other languages
English (en)
Inventor
Robin Edwin Buckingham
Stephen Alistair Smith
Original Assignee
Smithkline Beecham Plc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=10816177&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DZ2564(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Smithkline Beecham Plc filed Critical Smithkline Beecham Plc
Application granted granted Critical
Publication of DZ2564A1 publication Critical patent/DZ2564A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/64—Sulfonylureas, e.g. glibenclamide, tolbutamide, chlorpropamide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
DZ980174A 1997-07-18 1998-07-15 Compositions pharmaceutiques pour le traitement dudiabète sucre et d'états associés. DZ2564A1 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB9715306A GB9715306D0 (en) 1997-07-18 1997-07-18 Novel method of treatment

Publications (1)

Publication Number Publication Date
DZ2564A1 true DZ2564A1 (fr) 2003-02-15

Family

ID=10816177

Family Applications (1)

Application Number Title Priority Date Filing Date
DZ980174A DZ2564A1 (fr) 1997-07-18 1998-07-15 Compositions pharmaceutiques pour le traitement dudiabète sucre et d'états associés.

Country Status (41)

Country Link
EP (1) EP0998291B2 (fr)
JP (2) JP2001510158A (fr)
KR (1) KR100680667B1 (fr)
CN (1) CN1264302A (fr)
AP (1) AP1318A (fr)
AR (2) AR016768A1 (fr)
AT (1) ATE366577T1 (fr)
AU (1) AU743269B2 (fr)
BG (1) BG64892B1 (fr)
BR (1) BR9810904A (fr)
CA (1) CA2297115C (fr)
CO (1) CO4940422A1 (fr)
CY (1) CY1107745T1 (fr)
CZ (1) CZ302668B6 (fr)
DE (1) DE69838066T3 (fr)
DK (1) DK0998291T4 (fr)
DZ (1) DZ2564A1 (fr)
EA (1) EA003303B1 (fr)
ES (1) ES2290989T5 (fr)
GB (1) GB9715306D0 (fr)
HK (1) HK1029272A1 (fr)
HU (1) HU229119B1 (fr)
ID (1) ID24198A (fr)
IL (1) IL134045A0 (fr)
IN (1) IN189035B (fr)
MA (1) MA26522A1 (fr)
MY (1) MY138246A (fr)
NO (1) NO326356B1 (fr)
NZ (3) NZ520652A (fr)
OA (1) OA11632A (fr)
PE (1) PE99799A1 (fr)
PL (2) PL338127A1 (fr)
PT (1) PT998291E (fr)
SI (1) SI0998291T2 (fr)
SK (2) SK287823B6 (fr)
TR (1) TR200000135T2 (fr)
TW (1) TW586926B (fr)
UA (1) UA70302C2 (fr)
UY (1) UY25103A1 (fr)
WO (1) WO1999003476A1 (fr)
ZA (1) ZA986365B (fr)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1832291A3 (fr) * 1999-07-13 2009-11-04 Medicure Inc. utilisation de pyridoxal phosphate pour le traitement du diabete
EP1897547A1 (fr) * 1999-07-13 2008-03-12 Medicure Inc. Utilisation de dérivés de phosphate de pyridoxal dans le traitement du diabète et de ses complications correspondantes
US6586438B2 (en) 1999-11-03 2003-07-01 Bristol-Myers Squibb Co. Antidiabetic formulation and method
US20010036479A1 (en) 2000-01-14 2001-11-01 Gillian Cave Glyburide composition
CA2434169C (fr) 2001-01-12 2011-03-15 Sun Pharmaceutical Industries Limited Systeme de liberation espacee de medicaments
WO2005041962A1 (fr) 2003-10-31 2005-05-12 Takeda Pharmaceutical Company Limited Preparation solide comprenant un sensibilisateur a l'insuline, un secretagogue d'insuline et un ester d'acide gras de polyoxyethylene sorbitan
JP2008019169A (ja) * 2004-10-25 2008-01-31 Osaka Univ 新規ｐｐａｒ調節剤およびそのスクリーニング方法
BRPI0620020A2 (pt) 2005-12-22 2011-10-25 Takeda Pharmaceutical preparação sólida, e, partìcula revestida

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5522636A (en) * 1978-08-04 1980-02-18 Takeda Chem Ind Ltd Thiazoliding derivative
JPS5697277A (en) * 1980-01-07 1981-08-05 Takeda Chem Ind Ltd Thiazolidine derivative
JPS6051189A (ja) * 1983-08-30 1985-03-22 Sankyo Co Ltd チアゾリジン誘導体およびその製造法
US4582839A (en) * 1984-03-21 1986-04-15 Takeda Chemical Industries, Ltd. 2,4-thiazolidinediones
CN1003445B (zh) * 1984-10-03 1989-03-01 武田药品工业株式会社 噻唑烷二酮衍生物，其制备方法和用途
JPH06779B2 (ja) * 1985-06-10 1994-01-05 武田薬品工業株式会社 チアゾリジオン誘導体およびそれを含んでなる医薬組成物
US4812570A (en) * 1986-07-24 1989-03-14 Takeda Chemical Industries, Ltd. Method for producing thiazolidinedione derivatives
DE10199003I1 (de) * 1987-09-04 2003-06-12 Beecham Group Plc Substituierte Thiazolidinionderivate
US4791125A (en) * 1987-12-02 1988-12-13 Pfizer Inc. Thiazolidinediones as hypoglycemic and anti-atherosclerosis agents
WO1989008651A1 (fr) * 1988-03-08 1989-09-21 Pfizer Inc. Derives de thiaxolidinedione hypoglycemiques
US5061717A (en) * 1988-03-08 1991-10-29 Pfizer Inc. Thiazolidinedione hypoglycemic agents
WO1991007107A1 (fr) * 1989-11-13 1991-05-30 Pfizer Inc. Agents d'oxazolidinedione hypoglycemiques
JPH04210683A (ja) * 1990-12-06 1992-07-31 Terumo Corp チアゾリジン−２，４−ジオン誘導体およびこれを含有する糖尿病合併症治療薬
US5183823A (en) * 1991-04-11 1993-02-02 Takeda Chemical Industries, Ltd. Pyridine n-oxide compounds which are useful as hypoglycemic and hypolipidemic agents
DE69211450T2 (de) * 1991-08-16 1996-12-05 Sandoz Ag Inhalator zur Verabreichung von pulverförmigen Substanzen
ES2101866T3 (es) * 1991-08-26 1997-07-16 Upjohn Co Producto alimentario liquido que contiene acido 3-guanidinopropionico.
GB9218830D0 (en) * 1992-09-05 1992-10-21 Smithkline Beecham Plc Novel compounds
TWI238064B (en) * 1995-06-20 2005-08-21 Takeda Chemical Industries Ltd A pharmaceutical composition for prophylaxis and treatment of diabetes
US5859037A (en) * 1997-02-19 1999-01-12 Warner-Lambert Company Sulfonylurea-glitazone combinations for diabetes

Also Published As

Publication number Publication date
CN1264302A (zh) 2000-08-23
AR019331A2 (es) 2002-02-13
GB9715306D0 (en) 1997-09-24
DE69838066T2 (de) 2008-03-20
EA003303B1 (ru) 2003-04-24
KR20010021948A (ko) 2001-03-15
KR100680667B1 (ko) 2007-02-09
CO4940422A1 (es) 2000-07-24
NO20000229D0 (no) 2000-01-17
HUP0003634A2 (hu) 2001-07-30
UY25103A1 (es) 2000-12-29
PE99799A1 (es) 1999-12-22
MY138246A (en) 2009-05-29
ES2290989T3 (es) 2008-02-16
EA200000141A1 (ru) 2000-08-28
JP2001510158A (ja) 2001-07-31
DE69838066T3 (de) 2012-03-29
AU743269B2 (en) 2002-01-24
HK1029272A1 (en) 2001-03-30
SK288053B6 (sk) 2013-03-01
EP0998291B2 (fr) 2011-07-06
IL134045A0 (en) 2001-04-30
ES2290989T5 (es) 2011-11-11
CA2297115C (fr) 2010-02-23
DK0998291T3 (da) 2007-11-05
CY1107745T1 (el) 2013-04-18
IN189035B (fr) 2002-12-07
AR016768A1 (es) 2001-08-01
BR9810904A (pt) 2000-09-26
HU229119B1 (en) 2013-08-28
TR200000135T2 (tr) 2000-05-22
ZA986365B (en) 2000-01-17
AP1318A (en) 2004-10-22
WO1999003476A1 (fr) 1999-01-28
NZ520652A (en) 2004-06-25
NO20000229L (no) 2000-01-17
CA2297115A1 (fr) 1999-01-28
SI0998291T1 (sl) 2007-12-31
UA70302C2 (uk) 2004-10-15
EP0998291B1 (fr) 2007-07-11
PL199125B1 (pl) 2008-08-29
SK287823B6 (sk) 2011-11-04
PT998291E (pt) 2007-10-11
HUP0003634A3 (en) 2003-04-28
DE69838066D1 (de) 2007-08-23
OA11632A (en) 2004-11-22
AP2000001734A0 (en) 2000-03-31
BG104139A (en) 2000-11-30
PL338127A1 (en) 2000-09-25
SK602000A3 (en) 2000-07-11
NO326356B1 (no) 2008-11-17
TW586926B (en) 2004-05-11
CZ2000173A3 (en) 2001-05-16
CZ302668B6 (cs) 2011-08-24
BG64892B1 (bg) 2006-08-31
NZ515555A (en) 2002-09-27
NZ501256A (en) 2002-09-27
MA26522A1 (fr) 2004-12-20
AU8448798A (en) 1999-02-10
ATE366577T1 (de) 2007-08-15
JP2005247865A (ja) 2005-09-15
ID24198A (id) 2000-07-13
EP0998291A1 (fr) 2000-05-10
SI0998291T2 (sl) 2011-10-28
DK0998291T4 (da) 2011-09-26

Similar Documents

Publication Publication Date Title
MA26536A1 (fr) Association de compositions pharmaceutiques d'atorvastatine et d'agents antihypertensifs, et procede pour leur preparation.
MA26790A1 (fr) Composition dietetique ou pharmaceutique a l'usage pour la prevention ou le traitement de la hyper-oxalurie
DZ2494A1 (fr) Composition pharmaceutique d'oméprazole.
NL300258I1 (nl) Farmaceutische samenstelling voor toepassing in debehandeling van diabetes.
MA26420A1 (fr) Compositions pharmaceutiques mixtes pour le traitement de l'osteoporose, et procede pour leur preparation.
NO20063000L (no) Kombinasjon og farmasøytisk blanding for behandling av diabetes samt anvendelse derav.
DZ2675A1 (fr) Association pharmaceutique pour le traitement d'undysfunctionnement sexuel et compositions la conte nant.
MA26456A1 (fr) Formulations pharmaceutiques pour la distribution prolongee de medicament.
DZ2752A1 (fr) Composés et compositions pharmaceutiques pour le traitement du paludisme.
FR2732223B1 (fr) Composition pharmaceutique pour administration transdermique
NO20006630D0 (no) Farmasöytisk sammensetning for behandlingen av diabetes
MA26508A1 (fr) Formulations pharmaceutiques contenant du variconazole, et procede pour leur preparation.
FR2696074B1 (fr) Dispositif therapeutique en forme d'os pour chiens.
MA26516A1 (fr) Tartrate d'un dipeptide substitue, procede pour sa preparation et compositions pharmaceutiques le contenant.
OA09123A (fr) Composition pharmaceutique pour la prévention des maladies sexuellement transmissibles.
DZ2539A1 (fr) Compositions pharmaceutiques pour le traitement dela résistance à l'insuline.
MA26608A1 (fr) Procede de preparation d'une composition pharmaceutique destinee au traitement de l'insuffisance cardiaque.
DZ3014A1 (fr) Médicaments pour le traitement de l'hypertension.
ZA968990B (en) Pharmaceutical agents for the treatment of acute and chronic inflammatory diseases.
DZ2564A1 (fr) Compositions pharmaceutiques pour le traitement dudiabète sucre et d'états associés.
FR2703995B1 (fr) 5-acylamino 1,2,4-thiadiazoles, leur preparation et compositions pharmaceutiques en contenant.
FR2678170B1 (fr) Compositions orales pour la prevention d'odontonecrose et de maladie paradentaire.
FR2712495B1 (fr) Application de l'Óoenotheine B pour obtenir un médicament destiné au traitement des troubles liés à l'hyperandrogénie, et les compositions pharmaceutiques le contenant.
FR2705671B1 (fr) Nouveaux dérivés de l'hydroxybiphényle, leur préparation et les compositions pharmaceutiques qui les contiennent.
PH31643A (en) 2-Oxidole-1-carboxamide pharmaceutical agents for the treatment of alzheimer's disease.